Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirsevimab - Astrazeneca

Drug Profile

Nirsevimab - Astrazeneca

Alternative Names: Anti-RSV-4-monoclonal antibody - AstraZeneca; Anti-RSV-mAb-D25; Anti-RSV-MAb-YTE; Anti-RSV-monoclonal antibody - AstraZeneca; BEYFORTUS; Beyfortus; D25; MEDI 8897; nirsevimab-alip; Respiratory-syncytial-virus-monoclonal-antibody-D25; SP 0232

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AIMM Therapeutics
  • Developer AstraZeneca; Sanofi
  • Class Antivirals; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Respiratory syncytial virus infections

Most Recent Events

  • 18 Apr 2024 Quebec's National Institute of Excellence in Health and Social Services (INESSS) recommends nirsevimab to be used for the prevention of RSV lower respiratory tract disease (LRTD) in all neonates and infants aged 8 months and younger
  • 27 Mar 2024 Registered for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Japan (IM)
  • 27 Mar 2024 Nirsevimab receives Priority Review Designation for Respiratory syncytial virus infections in China prior to March 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top